Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 52Carcinoma, Renal Cell 47Neoplasm Metastasis 24Neoplasms 18Kidney Neoplasms 18Neuroendocrine Tumors 17Carcinoma, Non-Small-Cell Lung 13Tuberous Sclerosis 12Stomach Neoplasms 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Recurrence 10Prostatic Neoplasms 10Lymphoma 10Hodgkin Disease 10Glioblastoma 10Colorectal Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Brain Neoplasms 9Lymphoma, Follicular 8Lung Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma 8Waldenstrom Macroglobulinemia 7Triple Negative Breast Neoplasms 7Sarcoma 7Multiple Myeloma 7Lymphoma, B-Cell, Marginal Zone 7Glioma 7Central Nervous System Neoplasms 7

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Tuberous Sclerosis 2 × Everolimus × Clear all
NCT00790400 2017-02-17

EXIST-2

Novartis

Phase 3 Completed
118 enrolled 15 charts
CNS

Tuberous Sclerosis 2, Astrocytoma, Hereditary Sensory and Autonomic Neuropathies, Seizures, Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡